Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis. Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and prevent acute pancreatitis. This phase 2 trial (NCT03452228) evaluated evinacumab (angiopoietin-like 3 inhibitor) in thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenson, Robert S., Gaudet, Daniel, Ballantyne, Christie M., Baum, Seth J., Bergeron, Jean, Kershaw, Erin E., Moriarty, Patrick M., Rubba, Paolo, Whitcomb, David C., Banerjee, Poulabi, Gewitz, Andrew, Gonzaga-Jauregui, Claudia, McGinniss, Jennifer, Ponda, Manish P., Pordy, Robert, Zhao, Jian, Rader, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033404/
https://www.ncbi.nlm.nih.gov/pubmed/36879129
http://dx.doi.org/10.1038/s41591-023-02222-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033404/
https://www.ncbi.nlm.nih.gov/pubmed/36879129
http://dx.doi.org/10.1038/s41591-023-02222-w

Ejemplares similares